Efficacy of Lanthanum Carbonate and Sevelamer Carbonate as Phosphate Binders in Chronic Kidney Disease—A Comparative Clinical Study
Authors:
- Parminder NainPNParminder Nain
- Narendra NayakNNNarendra Nayak
- Mary C. MajMMMary C. Maj
- Rohit Kumar SinghRSRohit Kumar Singh
- Jaspreet KaurJKJaspreet Kaur
- Yujin JeongYJYujin Jeong
- Sabyasachi MaitySMSabyasachi Maity
- Reetuparna NathRNReetuparna Nath
- Robert H. HilgersRHRobert H. Hilgers
- Shreya NauhriaSNShreya Nauhria
- Samal NauhriaSNSamal Nauhria
Open Access
Abstract
(1) Background: Hyperphosphatemia is correlated with an increased rate of mortality and morbidity due to cardiovascular diseases in chronic kidney disease (CKD) patients. It can be improved by restricting dietary intake of phosphate and oral phosphate binders, such as lanthanum carbonate and sevelamer carbonate. (2) Objective: To evaluate the clinical efficacy of sevelamer carbonate in comparison to lanthanum carbonate as phosphate binders for the treatment of hyperphosphatemia in CKD patients. (3) Methods: A randomized control comparative clinical study was conducted for one year on 150 CKD patients associated with hyperphosphatemia, divided into two groups, i.e., Group 1 (n = 75) treated with sevelamer carbonate 800 mg thrice daily and Group 2 (n = 75) treated with lanthanum carbonate 500 mg thrice daily. The patients were assessed at the time of enrollment in the study, after three months and after six months from baseline for different parameters, i.e., complete blood count, liver function tests, renal function tests, electrolytes, and serum phosphate level. (4) Results: 150 CKD patients aged 51–60 participated in the study. The mean age of patients was 54 ± 4.6 years, and males (55.71%) were more common than females (44.29%). Hypertension was the common comorbidity in both groups with chronic kidney disease. After six months of treatment, the mean serum phosphate level was significantly decreased from 8.31 ± 0.09 mg/dL to 5.11 ± 0.18 (38%) in Group 1 and from 8.79 ± 0.28 mg/dl to 4.02 ± 0.12 (54%; p < 0.05) in Group 2, respectively. In both groups, no significant difference was found in other parameters such as parathyroid hormone, calcium, uric acid, LFT, RFT, CBC, etc. (5) Conclusion: Lanthanum carbonate is more efficacious in lowering serum phosphate concentrations and effectively managing hyperphosphatemia as compared to sevelamer carbonate.Keywords
This publication has 46 references indexed in Scilit:
- Lanthanum carbonate for the control of hyperphosphatemia in chronic renal failure patients: a new oral powder formulation – safety, efficacy, and patient adherencePatient Preference and Adherence, 2013
- Hyperphosphatemia in patients with ESRD: assessing the current evidence linking outcomes with treatment adherenceBMC Nephrology, 2013
- Renal phosphate handling: PhysiologyIndian Journal of Endocrinology and Metabolism, 2013
- What do we know about chronic kidney disease in India: first report of the Indian CKD registryBMC Nephrology, 2012
- Long-term treatment with lanthanum carbonate reduces mineral and bone abnormalities in rats with chronic renal failureNephrology Dialysis Transplantation, 2010
- Primary Care Management of Chronic Kidney DiseaseJournal of General Internal Medicine, 2010
- Lanthanum Carbonate Reduces Phosphorus Burden in Patients with CKD Stages 3 and 4Clinical Journal of the American Society of Nephrology, 2009
- Systematic review of the evidence underlying the association between mineral metabolism disturbances and risk of all-cause mortality, cardiovascular mortality and cardiovascular events in chronic kidney diseaseNephrology Dialysis Transplantation, 2008
- Long-Term Efficacy and Safety Profile of Lanthanum Carbonate: Results for up to 6 Years of TreatmentNephron Clinical Practice, 2008
- Risk of developing end-stage renal disease in a cohort of mass screeningKidney International, 1996